Esperion Therapeutics, Inc.
ESPREsperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How ESPR's past catalysts played out
Ezetimibe
Hypercholesterolemia
Bempedoic Acid
Hyperlipidemias
Bempedoic acid 180 mg tablet
Cardiovascular Diseases
ETC-1002
Hyperlipidemia
bempedoic acid 180mg
Hypercholesterolemia
Ezetimibe 10mg
Hypercholesterolemia
Atorvastatin
Hypercholesterolemia
Bempedoic acid + Ezetimibe FDC Oral Tablet
Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Bempedoic Acid | Phase 3 | Hyperlipidemias | - | - |
Bempedoic acid 180 mg tablet | Phase 3 | Cardiovascular Diseases | - | - |
ETC-1002 | Phase 3 | Hyperlipidemia | - | - |
bempedoic acid 180mg | Phase 2 | Hypercholesterolemia | - | - |
Ezetimibe 10mg | Phase 2 | Hypercholesterolemia | - | - |
Atorvastatin | Phase 2 | Hypercholesterolemia | - | - |
Bempedoic acid + Ezetimibe FDC Oral Tablet | Phase 2 | Diabetes | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Esperion Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Esperion Therapeutics, Inc.'s (ESPR) pipeline across Phase 3, Phase 2. Its lead program is Ezetimibe (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Esperion Therapeutics, Inc.'s next FDA catalyst?→
Esperion Therapeutics, Inc.'s (ESPR) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ESPR biotech catalysts?→
Add ESPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Esperion Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.